Health
1 read
Pfizer's Lyme Disease Vaccine Shows 70% Effectiveness Pending Approval

Want the full story?
Read the complete article at KTSM
AI Summary
Pfizer has announced that its Lyme disease vaccine demonstrates a 70% effectiveness rate in preventing the illness, pending regulatory approval. If authorized, this vaccine would be the first of its kind for humans, addressing a significant health concern as Lyme disease cases continue to rise. The development is crucial for public health, especially in regions where Lyme disease is prevalent. Residents should stay informed about the vaccine's approval process and potential availability.
health vaccine lyme-disease pfizer
People & Organizations
Pfizer